Publications by authors named "Yaling Long"

Claim this Profile
N
Natural compound triptolide induces caspase-3/GSDME-mediated pyroptosis by promoting ROS accumulation in small cell lung cancer.
Yuheng Yan, Zhaolin Xu, Chengyan Wang, Ying Liu, Yaling Long

Cancer Cell Int· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway.
Jiali Wang, Xianhai He, Zhirong Jia, Aiwen Yan, Kang Xiao, Yaling Long

Pharm Biol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation.
Shanshan Huang, Yaling Long, Yuan Gao, Wanling Lin, Lei Wang

Exp Hematol Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi-center study.
Yi Qin, Yaling Long, Yuan Tang, Yuke Tian, Juan Li

Cancer Sci· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Notch signaling pathway: architecture, disease, and therapeutics.
Binghan Zhou, Wanling Lin, Yaling Long, Yunkai Yang, Huan Zhang

Signal Transduct Target Ther· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of STK11 mutation on acquired resistance to immunotherapy in advanced non-small cell lung cancer with Lynch syndrome: a case report and literature review.
Yaling Long, Yuan Tang, Chengzhi Cai, Min Yu, Min Zhang

Ann Palliat Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.
Yaling Long, Kai Zhang, Yanying Li, Min Yu, Jiao Zhu

Ann Palliat Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coexisting of and Acquired in a Lung Adenocarcinoma with Rearrangements Loss During the Treatment of Crizotinib and Ceritinib: A Case Report.
Chengzhi Cai, Yaling Long, Yanying Li, Meijuan Huang

Onco Targets Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis